Zobrazeno 1 - 10
of 410
pro vyhledávání: '"NOT EVALUABLE"'
Publikováno v:
International Journal of Disaster Resilience in the Built Environment, 2024, Vol. 15, Issue 5, pp. 793-805.
Publikováno v:
Land, Vol 11, Iss 7, p 1008 (2022)
In the process of development, traditional villages, as important tourism resources, have been impacted by external factors and lost their original authenticity. Looking for the important factors affecting its tourism development, in an attempt to as
Externí odkaz:
https://doaj.org/article/9fde3307e3a749f4b76fb982b26ab602
Autor:
Leş, Ioan
Publikováno v:
Curierul judiciar / Judicial Courier. (06):328-332
Externí odkaz:
https://www.ceeol.com/search/article-detail?id=571763
Autor:
Paul C Langley
Publikováno v:
INNOVATIONS in Pharmacy, Vol 8, Iss 1 (2017)
In 2016 the Dutch National Health Care Institute (Zorginstituut Nederland) published a new guidance for economic evaluations in healthcare to support reimbursement decisions. These Guidelines update and replace three previously published guidelines c
Externí odkaz:
https://doaj.org/article/971cd7696a7c4b4090cabf59810945b8
Autor:
Ursa Brown-Glaberman, Jose I. Mayordomo, William J. Gradishar, Jennifer R. Diamond, Andrew Brenner, Pavani Chalasani, Alison Stopeck, Virginia F. Borges, Peter Kabos, Elena Shagisultanova
Publikováno v:
Cancer Research. 81:PS10-03
Background: In hormone receptor-positive / HER2-positive (HR+/HER2+) breast cancer, the HER2 and estrogen receptor (ER) signals merge on the cyclin D1-CDK4/6-RB1 pathway. Thus, a combined pharmacological intervention with individual drugs targeting H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6a727bac3dbe9710f7b468b00923082
https://doi.org/10.1158/1538-7445.sabcs20-ps10-03
https://doi.org/10.1158/1538-7445.sabcs20-ps10-03
Autor:
de Gaynesford, Maximilian, author
Publikováno v:
The Rift in The Lute : Attuning Poetry and Philosophy, 2017.
Externí odkaz:
https://doi.org/10.1093/acprof:oso/9780198797265.003.0010
Autor:
Paul C Langley
Publikováno v:
INNOVATIONS in Pharmacy, Vol 7, Iss 2 (2016)
The question of demarcation between normal science and pseudoscience is critical to the discovery of new facts. The core elements supporting progress in science are: (i) empirically evaluable coherent theories and (ii) the testing of hypotheses throu
Externí odkaz:
https://doaj.org/article/4afcacc2537340c8a8d6cc2759c265de
Autor:
Georg Kägi, Stefan Hägele-Link, Johannes Weber, Oliver Bozinov, Fabian Cavalloni, Deborah Brogle, Florian Brugger, Yashar Naseri, Peter C. Reinacher, Marie T. Krüger
Publikováno v:
Acta Neurochirurgica. 163:197-203
The two middle contacts of directional leads (d-leads) for deep brain stimulation are split into three segments, allowing current steering toward desired axial directions. To facilitate programming, their final orientation needs to be reliably determ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed68f5bc26791c5cd31dde0aac8022a6
https://doi.org/10.1007/s00701-020-04568-3
https://doi.org/10.1007/s00701-020-04568-3
Autor:
Christopher J. Darus, Danijela Jelovac, Linda R. Duska, Gina R. Petroni, Lisa Barroilhet, Jubilee Brown, Nikole Varhegyi, Kathleen N. Moore, Angeles Alvarez Secord, William P. McGuire
Publikováno v:
Gynecologic Oncology. 157:585-592
Angiogenesis inhibition is a valuable strategy for ovarian cancer (EOC). Pazopanib (paz) is a potent small molecular inhibitor of VEGF-1, -2, -3, PDGFR, c-kit, and has activity as a single agent in ovarian cancer. We designed a trial to assess the be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eab2ff6d023daeab28e617f8741af219
https://doi.org/10.1016/j.ygyno.2019.10.014
https://doi.org/10.1016/j.ygyno.2019.10.014
Autor:
Stacey L. Berg, Kara L. Davis, Brenda J. Weigel, Charles G. Minard, Crystal L. Mackall, Elizabeth Fox, Rachel A. Kudgus, Stephan D. Voss, Melinda S. Merchant, Joel M. Reid, Xiaowei Liu
Publikováno v:
Lancet Oncol
Summary Background Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on these drugs in children are scarce. We did a phase 1–2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93d6ae43767c81fa6c834573bde8ae37
https://doi.org/10.1016/s1470-2045(20)30023-1
https://doi.org/10.1016/s1470-2045(20)30023-1